The "Weight" for a New Agent Is Almost Over: A Commentary on the Novel Triagonist Retatrutide for Obesity.
Deravi. Maryam M; Piszczatoski. Chris C; Phillips. Bradley B; Huston. Jessica J; Vascimini. Angelina A
Key Findings
- Phase II trials reported up to 24% body weight loss.
- Waist circumference reductions of nearly 20 cm were observed.
- The most common adverse events were gastrointestinal (nausea, vomiting, diarrhea).
Practical Outcomes
- For now, retatrutide isn’t available outside clinical studies, so you can’t use it yet. However, the strong weight‑loss numbers suggest it could become a powerful tool for future obesity‑oriented protocols. Keep an eye on upcoming Phase III results for safety, dosing, and real‑world applicability.
Summary
Retatrutide is a new drug that hits three hormone receptors (glucagon, GLP‑1, and GIP) and has shown in early trials that people can lose up to about a quarter of their body weight and shrink their waist by almost 20 cm, with the main side‑effects being stomach upset.
Abstract
Retatrutide, a hormone receptor agonist targeting glucagon, glucagon-like peptide 1, and glucose-dependent insulinotropic polypeptide, is being developed to treat obesity. A literature review from April 2019 to April 2024 included such terms as "retatrutide," "LY3437943," "overweight," and "obesity." Phase I proof-of-concept studies led to phase II trials showing up to 24% body weight reduction and nearly 20 cm waist circumference reduction. The most common adverse effects were gastrointestinal. Ongoing phase II and III studies aim to further evaluate the safety and efficacy of retatrutide as a novel triagonist for obesity treatment.
Study Information
pubmed
2024
2024-10-19T00:00:00.000Z
10.1177/87551225241285326
1
15